Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Brain tumor, child: Other
Trial Type:  Treatment
Results 1-25 of 58 for your search:
Start Over
Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma
Phase: Phase III
Type: Supportive care, Treatment
Age: 3 to 21 at diagnosis
Trial IDs: ACNS0331, NCI-2009-00335, CDR0000365506, COG-ACNS0331, NCT00085735
Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: Under 3
Trial IDs: ACNS0334, NCI-2009-00338, CDR0000483683, COG-ACNS0334, NCT00336024
Chemotherapy and Radiation Therapy in Treating Young Patients with Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 21
Trial IDs: ACNS0332, NCI-2009-00336, CDR0000511991, COG-ACNS0332, NCT00392327
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 21
Trial IDs: ACNS0831, NCI-2011-02029, CDR0000668560, COG-ACNS0831, NCT01096368
Combination Chemotherapy in Treating Patients with Non-Metastatic Extracranial Ewing Sarcoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 50 and under
Trial IDs: AEWS1031, NCI-2011-02611, CDR0000687639, COG-AEWS1031, NCT01231906
Combination Chemotherapy and Fixed or Flexible Administration of Filgrastim in Treating Younger Patients With Cancer
Phase: Phase III
Type: Treatment
Age: 1 to 25
Trial IDs: 2013-062, NCI-2013-02001, NCT01987596
Crizotinib in Treating Younger Patients with Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 21
Trial IDs: ADVL0912, NCI-2011-01937, CDR0000647587, COG-ADVL0912, NCT01182896, P10666, NCT00939770
Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients with Recurrent or Progressive CNS Embryonal or Germ Cell Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 1 to 30
Trial IDs: SOL-08131-L, NCI-2013-00790, 5056, MR00042551, OHSU-5056, NCT00983398
Selumetinib in Treating Young Patients with Recurrent or Refractory Low Grade Glioma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 to 21
Trial IDs: PBTC-029B, NCI-2012-03173, CDR667932, PBTC-029, NCT01089101
Vorinostat and Etoposide in Treating Younger Patients With Refractory or Relapsed Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 4 to 21
Trial IDs: 10-096, NCI-2011-00493, NCT01294670
Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and under
Trial IDs: PBTC-033, NCI-2012-00082, 12-C-0213, CDR0000717423, NCT01507324, P12978, NCT01514201
Radiation Therapy in Treating Patients With Recurrent or Progressive Brain Stem Glioma Previously Treated With Radiation Therapy
Phase: Phase II, Phase I
Type: Treatment
Age: 17 and under
Trial IDs: 2011-0804, NCI-2011-03725, NCT01469247
Aerosolized Aldesleukin in Treating Patients with Lung Metastases
Phase: Phase II, Phase I
Type: Treatment
Age: 12 and over
Trial IDs: 2010-0700, NCI-2012-00788, NCT01590069
Rituximab in Treating Patients with Relapsed or Refractory Lymphoid Malignancies Involving the Central Nervous System
Phase: Phase II, Phase I
Type: Treatment
Age: 3 and over
Trial IDs: 2011-0844, NCI-2012-00849, NCT01596127
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 2 to 18
Trial IDs: TED12689, NCI-2014-00195, U1111-1128-5704, NCT01751308
WEE1 inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients with Relapsed or Refractory Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 21
Trial IDs: ADVL1312, NCI-2014-00547, NCT02095132
Multitargeted Tyrosine Kinase Inhibitor PLX3397 in Treating Patients with Refractory Leukemias or Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 30
Trial IDs: 15-C-0093, NCI-2015-00457, 150093, P141640, NCT02390752
Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma
Phase: Phase II
Type: Treatment
Age: 21 and under
Trial IDs: V0706, NCI-2014-00478, NCT00601003
Proton Beam Radiation Therapy in Treating Patients with Medulloblastoma and Pineoblastoma
Phase: Phase II
Type: Treatment
Age: 3 to 25
Trial IDs: DFCI 09-361, NCI-2010-01328, NCT01063114
Everolimus in Treating Younger Patients With Neurofibromatosis Type 1 or Low Grade Gliomas That Did Not Responded to Chemotherapy
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 21
Trial IDs: 09452, NCI-2010-01929, DOD W81XWH-05-1-0615, NCT01158651
Radiation Therapy, Bevacizumab, Erlotinib Hydrochloride, or Temozolomide in Treating Younger Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 18
Trial IDs: 10-321, NCI-2011-03059, DFCI 10-321, NCT01182350
Poly ICLC in Treating Younger Patients With Recurrent or Progressive Low Grade Gliomas
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 0 to 21
Trial IDs: Poly-ICLC, NCI-2013-02084, NCT01188096
Temozolomide and Irinotecan Hydrochloride with or without Bevacizumab in Treating Young Patients with Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors
Phase: Phase II
Type: Treatment
Age: 21 and under
Trial IDs: ACNS0821, NCI-2011-02605, CDR0000686608, COG-ACNS0821, NCT01217437
Proton Beam Radiation Therapy in Treating Younger Patients with Brain Tumors
Phase: Phase II
Type: Natural history/Epidemiology, Treatment
Age: 1 to 25
Trial IDs: 10-206, NCI-2011-00201, NCT01288235
Start Over